Rational Advisors Inc. Makes New $2.92 Million Investment in Medtronic PLC $MDT

Posted by Francis Steltz on Jun 3rd, 2026

Rational Advisors Inc. purchased a new position in Medtronic PLC (NYSE:MDT – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,400 shares of the medical technology company’s stock, valued at approximately $2,920,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lodestone Wealth Management LLC purchased a new stake in Medtronic in the fourth quarter worth about $27,000. Anfield Capital Management LLC increased its position in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Medtronic in the fourth quarter worth about $29,000. GoalVest Advisory LLC purchased a new stake in Medtronic in the fourth quarter worth about $29,000. Finally, Imprint Wealth LLC purchased a new stake in Medtronic in the third quarter worth about $31,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

MDT has been the subject of a number of analyst reports. Mizuho reduced their price target on Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Piper Sandler cut their target price on Medtronic from $105.00 to $91.00 and set a “neutral” rating for the company in a research report on Wednesday, April 1st. Leerink Partners reiterated an “outperform” rating and set a $119.00 target price on shares of Medtronic in a research report on Tuesday, March 10th. Truist Financial cut their target price on Medtronic from $103.00 to $95.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. Finally, Weiss Ratings cut Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 21st. Fifteen research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $106.45.

Read Our Latest Stock Report on MDT

Medtronic Stock Performance

NYSE:MDT opened at $73.72 on Wednesday. The stock has a 50-day moving average price of $82.11 and a 200 day moving average price of $92.49. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The stock has a market capitalization of $94.65 billion, a P/E ratio of 20.54, a P/E/G ratio of 1.76 and a beta of 0.58. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.9%. Medtronic’s dividend payout ratio is presently 79.11%.

About Medtronic

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).